Senkyunolide ICAS# 94596-28-8 |
- Senkyunolide H
Catalog No.:BCN6352
CAS No.:94596-27-7
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 94596-28-8 | SDF | Download SDF |
| PubChem ID | 11521428 | Appearance | Powder |
| Formula | C12H16O4 | M.Wt | 224.3 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (3Z,6S,7S)-3-butylidene-6,7-dihydroxy-4,5,6,7-tetrahydro-2-benzofuran-1-one | ||
| SMILES | CCCC=C1C2=C(C(C(CC2)O)O)C(=O)O1 | ||
| Standard InChIKey | DQNGMIQSXNGHOA-JXQVETIVSA-N | ||
| Standard InChI | InChI=1S/C12H16O4/c1-2-3-4-9-7-5-6-8(13)11(14)10(7)12(15)16-9/h4,8,11,13-14H,2-3,5-6H2,1H3/b9-4-/t8-,11+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Senkyunolide I may be an active component of L. chuanxiong, traditionally used to treat migraine, it can protect rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3, the neuroprotective mechanisms of itI are associated with its anti-oxidation and anti-apoptosis properties. Senkyunolide I can reduce the metamorphose damage of the RBC caused by ConA, the aggregation of the RBC can be alleviated by it. |
| Targets | ERK | Nrf2 | HO-1 | Bcl-2/Bax | Caspase | 5-HT Receptor | NO |
| In vitro | Effects of Ferulic Acid,Senkyunolide H and Senkyunolide I on Erythrocytes[Reference: WebLink]Lishizhen Medicine & Materia Medica Research, 2003, 14(12):738-9.To study the effects of Ferulic acid、Senkyunolide H and Senkyunolide I on erythrocytes deformability and aggregation. |
| In vivo | Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3.[Pubmed: 25698615]Brain Res. 2015 Apr 24;1605:39-48.Oxidative damage and apoptosis are critical factors contributing to neuronal death during a stroke. The aim of the present study was to evaluate the neuroprotective effects of Senkyunolide I (SEI) on focal cerebral ischemia-reperfusion (I/R) injury in rats, and investigate the underlying mechanisms. Identification of senkyunolide I metabolites in rats using ultra performance liquid chromatography/quadrupole-time-of-flight tandem mass spectrometry.[Pubmed: 23666254]J Pharm Biomed Anal. 2013 Jul-Aug;81-82:178-86.Ligusticum chuanxiong Hort. (Umbelliferae) has been widely prescribed to treat cardiovascular disease in China for centuries. Senkyunolide I is one of the major bioactive components in L. chuanxiong, which shows pharmacological activities against migraines and oxidative damage. |
| Animal Research | Effect and mechanism of senkyunolide I as an anti-migraine compound from Ligusticum chuanxiong.[Pubmed: 21235591 ]J Pharm Pharmacol. 2011 Feb;63(2):261-6.To evaluate the analgesic and anti-migraine activities of Senkyunolide I from Ligusticum chuanxiong. |
Senkyunolide I Dilution Calculator
Senkyunolide I Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4583 mL | 22.2916 mL | 44.5831 mL | 89.1663 mL | 111.4579 mL |
| 5 mM | 0.8917 mL | 4.4583 mL | 8.9166 mL | 17.8333 mL | 22.2916 mL |
| 10 mM | 0.4458 mL | 2.2292 mL | 4.4583 mL | 8.9166 mL | 11.1458 mL |
| 50 mM | 0.0892 mL | 0.4458 mL | 0.8917 mL | 1.7833 mL | 2.2292 mL |
| 100 mM | 0.0446 mL | 0.2229 mL | 0.4458 mL | 0.8917 mL | 1.1146 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Senkyunolide H
Catalog No.:BCN6352
CAS No.:94596-27-7
- Parisyunnanoside B
Catalog No.:BCN2837
CAS No.:945865-37-2
- AA 29504
Catalog No.:BCC7829
CAS No.:945828-50-2
- XL019
Catalog No.:BCC2057
CAS No.:945755-56-6
- 7-O-ethyl-morroniside
Catalog No.:BCN3883
CAS No.:945721-10-8
- 6-Aldehydo-7-methoxyiso-ophiopogonanone B
Catalog No.:BCC8345
CAS No.:123941-06-0
- (R)-(+)-m-Nitrobiphenyline oxalate
Catalog No.:BCC7525
CAS No.:945618-97-3
- Pexmetinib (ARRY-614)
Catalog No.:BCC6509
CAS No.:945614-12-0
- AMG-900
Catalog No.:BCC2175
CAS No.:945595-80-2
- Levcromakalim
Catalog No.:BCC7039
CAS No.:94535-50-9
- 9(11),12-Oleanadien-3-ol
Catalog No.:BCN4499
CAS No.:94530-87-7
- Senkyunolide G
Catalog No.:BCC9143
CAS No.:94530-85-5
- LX-1031
Catalog No.:BCC1712
CAS No.:945976-76-1
- RO5126766(CH5126766)
Catalog No.:BCC6374
CAS No.:946128-88-7
- Mulberrofuran K
Catalog No.:BCN7188
CAS No.:94617-36-4
- RN 1734
Catalog No.:BCC7770
CAS No.:946387-07-1
- LY2409881
Catalog No.:BCC5650
CAS No.:946518-60-1
- Hyperectine
Catalog No.:BCN3406
CAS No.:94656-46-9
- MNI 137
Catalog No.:BCC6156
CAS No.:946619-21-2
- Rhodiolgin; Gossypetin-7-O-α-rhamnopyranoside
Catalog No.:BCC8247
CAS No.:94696-39-6
- Gypenoside XLVI
Catalog No.:BCN3863
CAS No.:94705-70-1
- PF 429242
Catalog No.:BCC6009
CAS No.:947303-87-9
- Fmoc-Aib-OH
Catalog No.:BCC3149
CAS No.:94744-50-0
- Salmeterol xinafoate
Catalog No.:BCC1920
CAS No.:94749-08-3
Identification of senkyunolide I metabolites in rats using ultra performance liquid chromatography/quadrupole-time-of-flight tandem mass spectrometry.[Pubmed:23666254]
J Pharm Biomed Anal. 2013 Jul-Aug;81-82:178-86.
Ligusticum chuanxiong Hort. (Umbelliferae) has been widely prescribed to treat cardiovascular disease in China for centuries. Senkyunolide I is one of the major bioactive components in L. chuanxiong, which shows pharmacological activities against migraines and oxidative damage. In this paper, ultra performance liquid chromatography/quadrupole-time-of-flight tandem mass spectrometry (UPLC/Q-TOF-MS) was applied for the rapid analysis of Senkyunolide I metabolites in rats after its intravenous administration. The non-metabolized parent compound and eighteen metabolites from drug-treated samples in rat plasma, urine and bile were identified. Our analysis indicated that methylation, hydration, epoxidation, glucuronidation and glutathione conjugation were the major pathways of Senkyunolide I metabolism in vivo. This study provides important information regarding the metabolism of Senkyunolide I, which will be helpful for understanding its mechanism of action. Furthermore, this work demonstrates the potential of using UPLC/Q-TOF-MS for the rapid and reliable characterization of the metabolites of natural products.
Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3.[Pubmed:25698615]
Brain Res. 2015 Apr 24;1605:39-48.
Oxidative damage and apoptosis are critical factors contributing to neuronal death during a stroke. The aim of the present study was to evaluate the neuroprotective effects of Senkyunolide I (SEI) on focal cerebral ischemia-reperfusion (I/R) injury in rats, and investigate the underlying mechanisms. Male Sprague-Dawley rats were subjected to transient middle cerebral artery occlusion (tMCAO) for 2h, followed by 24h reperfusion, and then randomly assigned into four groups: Sham (sham-operated), Vehicle (tMCAO +normal saline), SEI-L (tMCAO +SEI 36 mg/kg) and SEI-H (tMCAO +SEI 72 mg/kg) groups. SEI was administered intravenously, 15 min after occlusion. Neurological deficit, brain edema and infarct volume were detected after 24h of reperfusion. Histological structures of cortices and hippocampus were observed by hematoxylin and eosin staining. Biochemical indexes in the cortex were assayed by colorimetry. The impact of SEI on the Nrf2-ARE-interaction was assayed using a luciferase reporter gene. Western blotting was performed to analysis the expressions of proteins related to anti-oxidation and apoptosis. SEI administration significantly ameliorated the neurological deficit, reduced the infarct volume and brain edema, reversed the cerebral morphologic damage, decreased the levels of MDA and increased the activities of superoxide dismutase. Furthermore, the high dose SEI could significantly activate the Nrf2/ARE pathway by up-regulating the phosphorylation of Erk1/2 and inducing Nrf2 nuclear translocation with enhanced HO-1 and NQO1 expressions. Additionally, treatment with SEI remarkably promoted the ratio of Bcl-2/Bax and inhibited the expressions of cleaved caspase 3 and caspase 9. These results suggest that the neuroprotective mechanisms of SEI are associated with its anti-oxidation and anti-apoptosis properties.
Effect and mechanism of senkyunolide I as an anti-migraine compound from Ligusticum chuanxiong.[Pubmed:21235591]
J Pharm Pharmacol. 2011 Feb;63(2):261-6.
OBJECTIVE: To evaluate the analgesic and anti-migraine activities of Senkyunolide I from Ligusticum chuanxiong. METHODS: Mice were orally administered various doses of Senkyunolide I, and their pain levels were assessed in a hot-plate test and by application of acetic acid. The levels of 5-hydroxytryptamine (5-HT), 5-hydroxytryptophan (5-HTP), 5-hydroxyindoleacetic acid (5-HIAA), norepinephrine (NE) and dopamine (DA) in plasma and brain were assessed, and the monoamine turnover rates (5-HT/5-HTP, 5-HIAA/5-HT and NE/DA) were also calculated. RESULTS: Mice given Senkyunolide I at 16 and 32 mg/kg had significantly elevated pain thresholds in the hot-plate test, and a dose of 32 mg/kg also reduced the number of abdominal writhing responses caused by acetic acid. Significant improvements were observed in the neurotransmitter levels of the drug-treated rats compared with the saline-administered controls. Compared to the rats with nitroglycerin-induced migraines, the levels of nitric oxide in the plasma and whole brain of rats given Senkyunolide I were lower. CONCLUSIONS: The present study suggests that Senkyunolide I may be an active component of L. chuanxiong, traditionally used to treat migraine. The mechanism of pain relief in migraine model rats may be through adjusting the levels of monoamine neurotransmitters and their turnover rates, as well as decreasing nitric oxide levels in the blood and brain. Therefore, Senkyunolide I may be developed as a potential treatment for migraine pain.
